Stockscreener 앱 받기
0.2225
27.26%
-0.0834
전일 마감가:
$0.3059
열려 있는:
$0.26
하루 거래량:
185.70K
Relative Volume:
19.44
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-27.26%
1개월 성능:
-50.08%
6개월 성능:
-75.69%
1년 성능:
-92.59%
1일 변동 폭
$0.2057
$0.26
1주일 범위
$0.2057
$0.26
52주 변동 폭
$0.2057
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.2225 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada
NKGen Biotech Enters Stock Purchase Agreement - TipRanks
NKGen Biotech Delays Quarterly Report Filing - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire
NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan
NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq
NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India
NKGen Biotech secures amended loan terms with East West Bank - Investing.com
NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World
NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire
Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo
NKGen Biotech Delays Annual Report Filing - TipRanks
3 Stocks Near 52-Week Lows With Strong Rebound Potential - The Globe and Mail
NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq
NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire
Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire
NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire
Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan
NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa
NKGen Biotech secures $5 million convertible loan - Investing.com India
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks
NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India
NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire
NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan
NKGen Biotech, Inc. SEC 10-Q Report - TradingView
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - The Manila Times
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
Nkgen Biotech Inc (NKGN) 재무 분석
Nkgen Biotech Inc (NKGN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.27%
1.55%
자본화:
|
볼륨(24시간):